Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Infect Control Hosp Epidemiol ; 25(11): 967-73, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15566032

RESUMO

BACKGROUND: During a hospital obstetric rotation, a medical student demonstrated classic symptoms of pertussis. The diagnosis was confirmed by isolation of Bordetella pertussis. Because this exposure occurred in a high-risk hospital setting, control measures were undertaken to prevent transmission and illness. OBJECTIVES: To identify secondary cases of pertussis, to determine compliance with chemoprophylaxis recommendations, and to monitor for adverse events associated with chemoprophylaxis following a hospital exposure to pertussis. PATIENTS: More than 500 individuals were potentially exposed, including 168 neonates; antimicrobial chemoprophylaxis was administered to 281 individuals. Fifty-eight neonates and 194 adults began azithromycin chemoprophylaxis; 18 neonates and 2 adults began erythromycin chemoprophylaxis. METHODS: Active surveillance was instituted for (1) secondary cases of pertussis among healthcare coworkers, obstetric patients, their neonates, and labor companions and (2) antibiotic compliance and tolerance. RESULTS: No secondary cases of pertussis were confirmed by laboratory tests; however, 26 suspected cases and 5 clinically compatible cases were identified. Antibiotic courses were completed by 95% of the individuals who initiated therapy. Neonates taking azithromycin had statistically significantly less gastrointestinal distress compared with neonates taking erythromycin (12% vs 50%; P = .002); there were no cases of infantile hypertrophic pyloric stenosis. CONCLUSIONS: Although it was not possible to assess the effectiveness of the antibiotic regimens, the lack of laboratory-confirmed secondary cases suggests control measures were successful. Data from the 58 neonates who received azithromycin suggest it may be well tolerated in this age group.


Assuntos
Antibacterianos/efeitos adversos , Infecção Hospitalar/prevenção & controle , Controle de Infecções/métodos , Transmissão de Doença Infecciosa do Profissional para o Paciente/prevenção & controle , Coqueluche/tratamento farmacológico , Coqueluche/transmissão , Adulto , Bordetella pertussis/isolamento & purificação , Aleitamento Materno/estatística & dados numéricos , Infecção Hospitalar/epidemiologia , Feminino , Seguimentos , Gastroenteropatias/induzido quimicamente , Humanos , Recém-Nascido , Transmissão de Doença Infecciosa do Profissional para o Paciente/análise , Massachusetts , Unidade Hospitalar de Ginecologia e Obstetrícia/estatística & dados numéricos , Cooperação do Paciente/estatística & dados numéricos , Vigilância da População/métodos , Período Pós-Parto/efeitos dos fármacos , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/microbiologia , Estudantes de Medicina , Coqueluche/epidemiologia , Coqueluche/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA